
Next-Generation Radiopharmaceuticals Redefining Targeted Oncology


Designed to be the Most Potent Payload in Targeted Oncology

Three Independent Clinical-Stage Programs, Each Against a Distinct Target with Data in 2027

Deep Leadership Across Radiopharmaceutical and Drug Development

The Perspective Story in Four Parts

Radiopharmaceutical Therapy: A Category Still Early in Its Adoption Curve

Targeted Delivery of Payloads is Transforming Oncology Therapy

$45 Billion+ Addressable Market, Already Generating Blockbuster Radiopharmaceutical Revenue

Four Programs Address a Combined $45B+ Solid Tumor Market

Pipeline in Depth: The Data Behind Each Program

Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

Neuroendocrine TumorsBamzireotide Navoxetan (VMT-α-NET)


Ongoing Phase 1/2a to Establish Broad Therapeutic Window




Durable Ongoing Disease Control






Bamzireotide Navoxetan’s Compelling Profile Supports Pre-Phase 3 Activities

MelanomaLapemelanotide zapixetar

Checkpoint Inhibitors Transformed Melanoma Care but Still Leave Many Behind

Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma

Ongoing Phase 1/2a Open-Label Trial For Lapemelanotide Zapixetar in Melanoma

Preliminary Anti-tumor Activity Observed at 3.0 x 3 mCi Dose

Generally Well-Tolerated

Lapemelanotide Zapixetar Clinical Data Support Further Development

PSV359Advanced Solid Tumors

PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors

FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential

Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors

PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent

CCK2R81 a potential first-in-class in selected solid tumors

Perspective’s CCK2R81 in Medullary Thyroid Cancer Compared to FDG and Fluorodopa

Platform and Manufacturing

Optimizing Structural Chemistry:

Choosing the Right Isotope

Not All ²¹²Pb Programs Are Created Equal

Advancing a Theranostic Approach:

Direct-to-Hospital Delivery through Integrated Isotope Production

Reaching the Largest Addressable Market with Regional Manufacturing

Financial Strength and IP


Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain

A Decade of Deliberate, End-to-End Engineering

Built Over a Decade - The Platform Is Built; Pipeline Advancing


Abbreviations

APPENDIX – Backup Slides

Investment thesis

Engineering the Alpha Advantage in Targeted Oncology

Optimizing the Entire System for Targeted Oncology

Advancing a Diverse 212Pb-Based Oncology Portfolio

Market opportunity

Solid Tumors are an Attractive Market for Radiopharmaceuticals


2L+ Metastatic Melanoma Trials

Bamzireotide navoxetan (VMT-α-NET)

Designed with Broad Therapeutic Window

Dosimetry: Independent Investigator Findings

Dosimetry: Highlights from the Phase 1 Study

Baseline Patient Characteristics in NANETS 2026 Data Analysis

Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment

Lapemelanotide zapixetar (VMT01)

ICI Combo Rationale: Strong Synergy with Lapemelanotide Zapixetar in Melanoma

Metastatic Melanoma: Post Second line plus

PSV359



PSV359 is Active Against FAP-α Expression on Tumor and on Stroma

Platform and Manufacturing


Designed for Better Clinical Outcome

212Pb Uniquely Suited for Combination with Immune Checkpoint Inhibitors

Kinetics Matter: 212Pb Hits Hard and Fast for Strong Activity with Less Systemic Exposure



On-Demand Fulfillment at Regional Sites for Finished Product Delivery

Ideal for Regional Manufacturing

Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product

IP protection
